In the HER2-PDXR model, temsirolimus significantly decreased tumor growth when used as a single agent (114.3 ± 27.1 mm3; p-value: 0. 045), and its activity was enhanced by the addition of EGCG (94.9 ± 33.1 mm3). Here, ERBB2 is linked to neoplasm.